GRI Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 1.76%, SMA50 -54.74%, SMA200 -92.82%). The stock’s 14-day RSI is 27.83 (weak momentum), while the ATR of 0.62 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.17% below its high and over 22.86% above its low. Average 10-day trading volume of 53.42 thousand shares is below the 3-month average of 394.44 thousand, indicating normal recent market interest.

GRI Bio, Inc. generated EPS of -$240.26 over the past year. Five-year average earnings growth is 83.24%. Wall Street analysts project EPS growth of 80.04% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $1.01. The high target offers 1412.61% upside. The low target suggests -57.56% downside. The mean target is $24.00. This offers 908.4% upside. GRI Bio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by 15.32%. The prior quarter beat by 18.15%. Over the last six quarters, Apple has recorded several small beats. These include -99.63% in March 14, 2025.

GRI Bio, Inc. has 2.52 million shares outstanding. The public float is 2.51 million shares, elevated short interest at 7.14% of float. This equals 178.17 thousand shares. The short ratio is 0.67 days. Institutional investors hold 0.78% of the float. Insiders own 0.02%. Hertz Walter Marc holds 385.51 thousand shares, Chaturvedi Vipin has 172.19 thousand shares and Agro Albert has 172.19 thousand shares.

GRI Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $15.73. This means the shares are trading below this model’s fair value.

GRI Bio, Inc. (NASDAQ:GRI) closed at $2.38 USD, gaining $0.06 (2.81%) from the previous close of $2.31. The stock is currently mid-range between its 52-week high and low $2.10 and $80.36. With a market capitalization of about $213.80 thousand, GRI Bio, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.24). Key stats such as the average daily volume over the past year has been around 373.91 thousand shares, volume is running light vs its 52-week average. Headquartered in La Jolla, CA, GRI Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO W. Marc Hertz, the company employs approximately 3 people and listed since April 24, 2023. GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.

GRI Bio, Inc. trades at a P/E ratio of -0.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.01 and a price-to-book ratio of 0.2 suggesting the stock is closer to book value. The P/FCF stands at -0.02, also above market averages.

Our AI price prediction model suggests that GRI Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.94%, with price expected at $2.45 by May 07, 2026, within a range of $2.26 to $2.64 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by July 22, 2026, with a range of $0.00 to $8.64. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 23, 2027, within a range of $0.00 to $5.74 thousand.

GRI Bio, Inc. (NASDAQ:GRI) shares are flat -5.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows GRI Bio, Inc. trading at a premium to the broader market with a P/E of -0.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.84, suggesting 649.58% upside. Our AI forecast model points to short-term strength (2.94% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.